SpringWorks Therapeutics Inc Stock News

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executive Officer Bhavesh Ashar - Chief Commercial Officer Jim Cassidy - Chief Medical Officer Francis Perier - Chief Financial Officer Badreddin Edris - Chief Operating Officer Conference Call Participan...

STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place in London, United Kingdom on Tuesday, November 19, 2024 at 10:30 a.m. ET.

– Achieved $49.3 million in OGSIVEO ® (nirogacestat) net product revenue in the third quarter –

– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment –

– Mirdametinib treatment demonstrated significant confirmed objective response rates and a  manageable safety profile in adults and children with NF1-PN –

– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a median duration of therapy of approximately 3 years –

STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference, taking place in Boston, Massachusetts on Wednesday, November 13, 2024 at 1:00 p.m....

Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently submitted a marketing application for a second candidate. The stock has pulled back recently, even as SpringWorks has funding in place to get the company to profitability in the years ahead.